OnCo
peoplePerson

Katherine K. Matthay

Paediatric oncologist whose trials established transplant and 13-cis-retinoic acid for high-risk neuroblastoma.

Long-time chair of COG neuroblastoma studies. Led the CCG-3891 trial establishing myeloablative therapy and retinoic acid in high-risk neuroblastoma and pioneered 131I-MIBG therapy for relapsed disease.

Role
Professor Emerita of Pediatrics, UCSF; Children's Oncology Group neuroblastoma investigator
Specialisms
Paediatric oncologyNeuroblastomaMIBG therapy

Papers

2top
TitleJournalYear
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer GroupNew England Journal of Medicine1999
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group studyJournal of Clinical Oncology2009

Connected

5top

cancers

1
Neuroblastoma (paediatric)

technologies

1
Radioligand therapy (beta emitters)

drugs

1
EstablishedRadioligand therapy (beta, norepinephrine transporter)
131I-MIBG (iobenguane I-131) therapy

institutions

2
Children's Oncology Group (COG)UCSF Helen Diller Family Comprehensive Cancer Center